Semaglutide for Seniors: Evidence, Eligibility, Coverage

Semaglutide has no separate rule for adults 65 and older. It is approved for type 2 diabetes, heart risk and kidney disease in type 2 diabetes. In SELECT: 6.5% for heart attack, stroke, or death due to heart disease, vs 8% on placebo.

Brands: Ozempic, Wegovy and Rybelsus
Best result (SELECT): 6.5% for heart attack, stroke, or death due to heart disease
Medicare GLP-1 Bridge: $50 per month

Wegovy in brief

Time the medicine stays inside you

About 1 week is the half-life. After 7 d, half is gone; once five half-lives pass (35 d), about 3% is left.

Weight loss in the main trial

Over 68 weeks in STEP 1, 14.9% of body weight was lost, while the placebo group lost 2.4%.

Costs as time goes on

Monthly prices in US dollars come from the maker's price page, which lists the list price and self-pay offers.

Sources: FDA label (DailyMed), healthsystemtracker.org, prnewswire.com 1 2.

Who qualifies?

Semaglutide: who qualifies
Who sets the rule	Who qualifies
Ozempic	For adults with type 2 diabetes, this medicine lowers blood sugar when used with diet and exercise.
Ozempic	For adults with type 2 diabetes who also have heart disease, this medicine lowers the chance of heart attack, stroke, and heart-related death.
Ozempic	Adults with type 2 diabetes and chronic kidney disease face less risk when they take it. That risk includes kidney failure, heart-related death, and worsening kidney disease.
Wegovy	When an adult has heart disease and also has obesity or overweight, injection and tablets lower the risk of heart attack, stroke, and death related to the heart.
Wegovy	For children and adults aged 12 and older who have obesity, or adults with overweight and a weight-related condition, it supports weight loss with diet and activity and helps keep the weight off long term.
Wegovy	It treats MASH liver disease with moderate to advanced scarring (no cirrhosis) in adults (injection).
Wegovy	For adults, the tablets are approved for weight loss and heart risk.
Rybelsus	For adults with type 2 diabetes, this medicine lowers blood sugar when used with diet and exercise.
Rybelsus	Among high-risk adults who have type 2 diabetes, it lowers the risk of heart attack, stroke, or heart-related death.
Medicare GLP-1 Bridge	BMI 35 or higher, no condition needed
Medicare GLP-1 Bridge	Qualification requires BMI 30 or higher, plus either uncontrolled blood pressure, heart failure, or CKD 3a+
Medicare GLP-1 Bridge	People with BMI 27 or higher qualify if they also have PAD or prediabetes, or have had a heart attack or stroke

Sources: FDA label (DailyMed) 1 2 3, medicare.gov 1 2.

Trial results for seniors

Semaglutide trials in older adults
Trial	Medicine	Who took part	Length	People	Main result	Comparison
SELECT	Wegovy	Adults 45 and older with heart disease who were overweight or obese, without diabetes	39.8 months (follow-up)	17,604	6.5% for heart attack, stroke, or death due to heart disease	8% on placebo
SOUL	Rybelsus	Adults 50 and older who have heart or kidney disease along with type 2 diabetes	47.5 months (follow-up)	9,650	12% for heart attack, stroke, or death from heart disease	13.8% on placebo

Trial sources: SELECT (PubMed) and SOUL (PubMed).

What is different for seniors?

Semaglutide: label points for older adults
What changes	What the label says	Labels
Low Blood Sugar When Combined with Insulin Secretagogues or Insulin	Low blood sugar becomes more likely if you use insulin or a sulfonylurea with it. Those doses may need to be lower.	All of them
Acute Kidney Injury Due to Volume Depletion	Fluid loss from vomiting or diarrhea can lead to kidney injury. Drink fluids and report heavy fluid loss.	All of them
Heart Rate Increase	Can raise resting heart rate. Your heartbeat racing or pounding at rest should be reported to your doctor.	Wegovy
Taken with insulin or sulfonylureas	Your chance of low blood sugar goes up when this medicine is combined with insulin or with a sulfonylurea, such as glipizide or glimepiride; your doctor may lower those doses.	All of them

FDA labels on DailyMed: 1 2.

Warnings from the label: FDA label (DailyMed).

Coverage for seniors

For a diabetes or cardiovascular disease prescription, these medicines can be covered by Medicare Part D.

Coverage from Part D plans may apply to a GLP-1 used for type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease.

Medicare Part D does not pay for a GLP-1 when you take it only to lose weight.

Under the Medicare GLP-1 Bridge, Wegovy has a listed monthly price of $50 for people who meet its rules.

Wherever Medicaid covers weight-loss GLP-1s, prior authorization is the norm.

Sources: humana.com, medicare.gov, CMS, KFF.

Alternatives for seniors

GLP-1 medicines and older adults
Medicine	For older adults	How it is taken	Trial result
Ozempic	Approved uses apply	weekly injection	Not listed
Wegovy	Approved uses apply	weekly injection or daily tablet	6.5% for heart attack, stroke, or death due to heart disease
Rybelsus	Approved uses apply	daily tablet	12% for heart attack, stroke, or death from heart disease
Mounjaro	Approved uses apply	weekly injection	Not listed
Zepbound	Approved uses apply	weekly injection	Not listed
Foundayo	Approved uses apply	daily tablet	Not listed
Trulicity	Approved uses apply	weekly injection	12% for heart attack, stroke, or death from heart disease
Saxenda	Approved uses apply	daily injection	Not listed
Victoza	Approved uses apply	daily injection	Not listed
Byetta	Approved uses apply	twice-daily injection	Not listed